Blurbs

Analysts Offer Insights on Healthcare Companies: CTI BioPharma (CTIC) and Establishment Labs Holdings (ESTA)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CTI BioPharma (CTICResearch Report) and Establishment Labs Holdings (ESTAResearch Report) with bullish sentiments.

CTI BioPharma (CTIC)

In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on CTI BioPharma, with a price target of $12.00. The company’s shares closed last Monday at $7.06, close to its 52-week high of $7.80.

According to TipRanks.com, Cann is a 3-star analyst with an average return of 2.9% and a 45.5% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Syros Pharmaceuticals, and Intellia Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CTI BioPharma with a $8.70 average price target, representing a 15.5% upside. In a report issued on July 27, JMP Securities also maintained a Buy rating on the stock with a $6.00 price target.

See today’s best-performing stocks on TipRanks >>

Establishment Labs Holdings (ESTA)

In a report released yesterday, Marie Thibault from BTIG reiterated a Buy rating on Establishment Labs Holdings, with a price target of $90.00. The company’s shares closed last Monday at $66.79.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 10.0% and a 37.6% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Irhythm Technologies, Edwards Lifesciences, and Pear Therapeutics.

Establishment Labs Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $73.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTIC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos